{"doi":"10.1002/ana.410150615","title":"Azathioprine in the treatment of myasthenia gravis","abstract":"<jats:title>Abstract</jats:title><jats:p>Twenty‐four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.</jats:p>","journal":"Annals of Neurology","year":1984,"id":615556,"datarank":0.7064295301968502,"base_score":4.709530201312334,"endowment":4.709530201312334,"self_citation_contribution":0.7064295301968502,"citation_network_contribution":0.0,"self_endowment_contribution":0.7064295301968502,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":110,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":290341,"name":"David R. Cornblath","orcid":null,"position":1,"is_corresponding":false},{"id":1586701,"name":"Gareth J. Parry","orcid":null,"position":2,"is_corresponding":false},{"id":290620,"name":"Robert P. Lisak","orcid":null,"position":3,"is_corresponding":false},{"id":201841,"name":"Norman J. Schatz","orcid":null,"position":4,"is_corresponding":false},{"id":1586699,"name":"Arnold S. Witte","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Azathioprine in the treatment of myasthenia gravis","abstract":"<jats:title>Abstract</jats:title><jats:p>Twenty‐four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.</jats:p>","is_dataset_classified":null,"base_score":4.709530201312334,"endowment":4.709530201312334,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"6742794","pmcid":null,"openalex_id":"https://openalex.org/W2025863666","authors":[],"funders":[],"total_grants":0,"fwci":3.7945,"citation_percentile":0.93771946,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2013,"count":2},{"year":2014,"count":1},{"year":2016,"count":7},{"year":2017,"count":3},{"year":2018,"count":3},{"year":2019,"count":3},{"year":2020,"count":2},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":2},{"year":2024,"count":4},{"year":2025,"count":5},{"year":2026,"count":4}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.410150615","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.410150615","host_type":"publisher"},{"url":"https://doi.org/10.1002/ana.410150615","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/6742794","host_type":"repository"}],"fields_of_study":["Myasthenia Gravis and Thymoma","Pituitary Gland Disorders and Treatments","Adult","Aged","Azathioprine","Dose-Response Relationship, Drug","Drug Therapy, Combination","Female","Humans","Male","Middle Aged","Myasthenia Gravis","Prednisone","Recurrence"],"mesh_terms":["Adult","Aged","Azathioprine","Dose-Response Relationship, Drug","Drug Therapy, Combination","Female","Humans","Male","Middle Aged","Myasthenia Gravis","Prednisone","Recurrence"],"keywords":["Azathioprine","Medicine","Myasthenia gravis","Immunosuppression","Immunosuppressive drug","Surgery","Internal medicine","Gastroenterology","Transplantation","Disease"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T20:22:04.260966Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}